June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
R., B.
Author:
R. A H,
Author:
R. L K,
Author:
Raab, M.S.

PF597 HIGH DOSE MELPHALAN (200MG/M2) AND AUTOLOGOUS TRANSPLANTATION IN NEWLY-DIAGNOSED MULTIPLE MYELOMA UP TO THE AGE OF 70 YEARS: A SUBGROUP ANALYSIS FROM THE PHASE III GMMG-MM5 TRIAL

Mai, E.K.; Miah, K.; Merz, M.; More

HemaSphere. 3(S1):251-252, June 2019.

PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY

Dimopoulos, M.; Dytfeld, D.; Grosicki, S.; More

HemaSphere. 3(S1):626-627, June 2019.

Author:
Raaijmakers, M.

PS1121 ABSENCE OF GPI-NEGATIVE CELLS AT DIAGNOSIS AND LOW NEUTROPHIL COUNT 2 MONTHS AFTER ATGAM BASED TREATMENT ARE ASSOCIATED WITH LOWER 6-MONTH RESPONSE RATE IN ADULTS WITH (VERY) SEVERE APLASTIC ANEMIA

Tjon, J.; Bogers, L.; Wreede, L. de; More

HemaSphere. 3(S1):507-508, June 2019.

Author:
Raanani, P.

PF287 MIDOSTAURIN IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IS SAFE AND ASSOCIATED WITH IMPROVED REMISSION AND HIGHER TRANSPLANT RATES IN REMISSION - A MULTI-CENTER HISTORICAL CONTROL STUDY

Berger, T.; Rozovski, U.; Moshe, Y.; More

HemaSphere. 3(S1):95, June 2019.

PF325 REAL - LIFE DATA ON ROMIDEPSIN TREATMENT FOR RELAPSED AND REFRACTORY PERIPHERAL AND CUTANEOUS T-CELL LYMPHOMA - A MULTICENTER NATIONAL OBSERVATIONAL STUDY

Shimony, S.; Horowitz, N.; Ribakovsky, E.; More

HemaSphere. 3(S1):115, June 2019.

PF334 EPIDURAL/SPINAL ANESTHESIA IN PREGNANT JEWISH ASHKENAZI WOMEN HETEROZYGOTES FOR FACTOR XI DEFICIENCY, A SINGLE CENTER PROSPECTIVE STUDY

Shacham Abulafia, A.; Yaniv, Y.; Steimatzky, A.; More

HemaSphere. 3(S1):119, June 2019.

Author:
Rab, M.
Author:
Rabe, K.

PS1162 COMBINATION THERAPY TO PREVENT IBRUTINIB WITHDRAWAL: CONTINUED IBRUTINIB WITH THE ADDITION OF VENETOCLAX AT TIME OF PROGRESSION IN IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Hampel, P.; Call, T.; Ding, W.; More

HemaSphere. 3(S1):527-528, June 2019.

Author:
Rabe, K.G.
Author:
Rabian, F.
Author:
Rabin, N.

PF638 VENOUS AND ARTERIAL THROMBOTIC EVENTS IN MYELOMA PATIENTS TREATED WITH IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE (IRD) OR LENALIDOMIDE AND DEXAMETHASONE (RD)

Sayar, Z.; Yi, K.; Cheesman, S.; More

HemaSphere. 3(S1):272, June 2019.

PB2127 BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

Mahmood, A. S.; Sachchithanantham, S.; Harrison, S.; More

HemaSphere. 3(S1):958, June 2019.

Author:
Racil, Z.

PS1283 CLINICAL IMPLICATIONS OF AZOLE-RESISTANT VERSUS AZOLE-SUSCEPTIBLE INVASIVE ASPERGILLOSIS IN HEMATOLOGICAL MALIGNANCY (CLARITY) – A MULTICENTER STUDY

Cornely, O.A.; Seidel, D.; Arenz, D.; More

HemaSphere. 3(S1):587, June 2019.

Author:
Rácil, Z.

S1614 CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3(S1):744-745, June 2019.

Author:
Rad, R.
Author:
Radeski, D.
Author:
Radford, J.

S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY

Gallamini, A.; Straus, D.; Dlugosz-Danecka, M.; More

HemaSphere. 3(S1):362-363, June 2019.

PB1868 B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS

Chapiro, E.; Diop, K.; Dessen, P.; More

HemaSphere. 3(S1):851-852, June 2019.

Author:
Radia, D.

S830 AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM)

Radia, D.; Deininger, M.W.; Gotlib, J.; More

HemaSphere. 3(S1):368, June 2019.

Author:
Radich, J.

PF405 DASCERN 2-YEAR EXTENDED FOLLOW-UP OF DASATINIB EFFICACY AND SAFETY IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WHO HAVE SUBOPTIMAL RESPONSES TO 3 MONTHS OF IMATINIB

Saglio, G.; Jiang, Q.; Wang, J.; More

HemaSphere. 3(S1):154-155, June 2019.

Author:
Radich, J.P.

PF409 DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER STOPPING FRONTLINE (1L) NILOTINIB: ENESTFREEDOM 192-WK RESULTS

Ross, D.M.; Masszi, T.; Gómez Casares, M.T.; More

HemaSphere. 3(S1):157, June 2019.

Author:
Radinoff, A.

PS1465 SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB <10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL

Cervantes, F.; Gisslinger, H.; Radinoff, A.; More

HemaSphere. 3(S1):675-676, June 2019.

Author:
Radman, I.

PB1669 RISK FACTORS FOR THROMBOEMBOLISM IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Boban, A.; Mikulic, M.; Serventi-Seiwerth, R.; More

HemaSphere. 3(S1):771, June 2019.

PB1963 CHARACTERISTICS OF NEWLY DIAGNOSED AUTOIMMUNE HEMOLYTIC ANEMIA: 5-YEARS OF SINGLE-CENTER EXPERIENCE

Pulanic, D.; Raos, M.; Vinkovic, M.; More

HemaSphere. 3(S1):892, June 2019.

PB2327 SUBSTITUTING CARMUSTINE WITH BENDAMUSTINE IN BEAM RESULTS IN DELAYED PLATELET RECOVERY AND LESS MUCOSITIS WITH SIMILAR EFFICACY – A MATCHED PAIR ANALYSIS

Aurer, I.; Zekanovic, I.; Durakovic, N.; More

HemaSphere. 3(S1):1037, June 2019.

Author:
Radman, M.

PF773 LOWER SERUM LEVELS OF ZINC AND MAGNESIUM ARE ASSOCIATED WITH WORSE ORAL CGVHD AND DYSGEUSIA IN CGVHD PATIENTS

Mravak-Stipetic, M.; Radman, M.; Desnica, L.; More

HemaSphere. 3(S1):341, June 2019.

Author:
Radova, L.

PS1137 COMPLEX STRUCTURAL VARIANTS LEAD TO GENE INACTIVATION RATHER THAN EXPRESSION OF DE NOVO FUSION GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA

Plevova, K.; Hynst, J.; Zavacka, K.; More

HemaSphere. 3(S1):515, June 2019.

Author:
Radová, L.
Author:
Radtke, F.
Author:
Radu, E.
Author:
Radujkovic, A.
Author:
Radzhabova, A.

PB1744 THE ROLE OF FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA: THE EFFECT ON THE COURSE OF THE DISEASE AND THE RESULTS OF THERAPY

Radzhabova, A.; Voloshin, S.; Martynkevich, I.; More

HemaSphere. 3(S1):802, June 2019.

Author:
raffat, D.
Author:
Rafferty, B.

PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY

Dimopoulos, M.; Dytfeld, D.; Grosicki, S.; More

HemaSphere. 3(S1):626-627, June 2019.

Author:
Raffini, M.

PB2324 LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE

Paolini, S.; Romani, L.; Ottaviani, E.; More

HemaSphere. 3(S1):1036, June 2019.

Author:
Raffoux, E.

PF211 MITOCHONDRIAL PRIMING OF BLASTS, BUT NOT LSC, PREDICTS SURVIVAL IN OLDER AML PATIENTS TREATED INTENSIVELY INDEPENDENTLY OF ONCOGENETICS: A STUDY ON THE ALFA 1200 TRIAL

Dal Bello, R.; Adès, L.; Braun, T.; More

HemaSphere. 3(S1):57, June 2019.

PF261 A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF SELINEXOR VERSUS PHYSICIAN'S CHOICE (PC) IN OLDER PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

Sweet, K.; Blum, W.; Donner, H.; More

HemaSphere. 3(S1):82-83, June 2019.

PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG-120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

DiNardo, C.D.; Stein, A.S.; Stein, E.M.; More

HemaSphere. 3(S1):460-461, June 2019.

Author:
Ragab, I.
Author:
Ragaini, S.

PB1726 DOUBLE FLUDARABINE-BASED INDUCTION AND INFECTIVE RISK: THE BOLOGNA EXPERIENCE.

Sartor, C.; De Polo, S.; Lewis, R.E.; More

HemaSphere. 3(S1):794, June 2019.

PB2324 LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE

Paolini, S.; Romani, L.; Ottaviani, E.; More

HemaSphere. 3(S1):1036, June 2019.

Author:
Raghavan, M.
Author:
Raghoo, R.

PF519 MOLECULAR PROFILING OF PRIMARY BONE LYMPHOMA'S REVEALS FREQUENT MUTATIONS IN EZH2 AND OTHER EPIGENETIC GENES: IMPLICATIONS FOR TARGETED TREATMENT

Ibramoglu*, M. Suleiman; de Groen*, R.A.; van Eijk, R.; More

HemaSphere. 3(S1):212, June 2019.

Author:
Raheja, P.
Author:
Rahman, J.
Author:
Rahmanuddin, S.
Author:
Rahn, K.
Author:
Rai, R. Ph. D
Author:
Raia, M.
Author:
Raimondo, F. Di

PF585 GENE-EXPRESSION PROFILE OF HIGH-DENSITY NEUTROPHILS REVEALS PROGRESSIVE DIFFERENCES IN MGUS AND MULTIPLE MYELOMA, ASSOCIATED WITH REDUCED PHAGOCYTOSIS AND INCREASED INFECTION SUSCEPTIBILITY

Romano, A.; Parrinello, N.L.; Simeon, V.; More

HemaSphere. 3(S1):244, June 2019.

PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS

Montefusco, V.; Gay, F.; Spada, S.; More

HemaSphere. 3(S1):254-255, June 2019.

PF658 THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IS A CHEAP SURROGATE OF EXPANSION OF MYELOID-DERIVED SUPPRESSOR CELLS IN MYELOFIBROSIS BEFORE AND AFTER TREATMENT WITH RUXOLITINIB: A SINGLE-CENTER EXPERIENCE

Romano, A.; Parrinello, N.L.; Giallongo, C.; More

HemaSphere. 3(S1):281-282, June 2019.

PF674 OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS

Palandri, F.; Breccia, M.; Bonifacio, M.; More

HemaSphere. 3(S1):290, June 2019.

Author:
Rainford, Z.
Author:
Raiola, A.M.

PF759 ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES FROM HLA IDENTICAL SIBLINGS OR HAPLOIDENTICAL DONORS: A COMPARISON

Corbingi, A.; Dragonetti, G.; Galli, E.; More

HemaSphere. 3(S1):333-334, June 2019.

S1624 A DAY 100 LAB-SCORE PREDICTS EXTENSIVE CGVHD, OVERALL SURVIVAL AND TRANSPLANT-RELATED MORTALITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL ANALYSIS

Metafuni, E.; Cavattoni, I.; Lamparellli, T.; More

HemaSphere. 3(S1):750, June 2019.

Author:
Raitano, S.
Author:
Raj, A.